Pulmonx CORP (LUNG) — Who's Buying and Selling (13F, Q2 2026)

LUNG ranks #4416 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

108 institutions disclose a position in LUNG, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 0.5% of its own portfolio to it.

Cliff Asness has added to its LUNG position for two straight quarters, increasing it by $838.2K to reach $968.5K today.

Morgan Stanley has trimmed its LUNG position for two straight quarters, cutting it by $5.4M while still holding $3.8M.

LUNG is down 0% today, and institutions have been net sellers of $3.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

LUNG reported a net loss of $48.1M over the trailing twelve months.

• Not yet profitable — net loss of $48.1M over the trailing twelve months
• Revenue declined 3.4% year over year
• Net income improved year over year, from -$56.9M to -$48.1M
• Operating cash flow was negative, using $32.4M in cash
• Current ratio of 5.07x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.39x equity — within a conventional range